Is Drotrecogin alfa (activated) for adults with severe sepsis, cost-effective in routine clinical practice?

被引：0
|
作者：
M Zia Sadique
Richard Grieve
David A Harrison
Brian H Cuthbertson
Kathryn M Rowan
机构：
[1] London School of Hygiene and Tropical Medicine,Department of Health Services Research and Policy, WC1H 9SH
[2] Research Centre,Intensive Care National Audit &WC1H 9HR
[3] Sunnybrook Health Sciences Centre,Department of Critical Care Medicine, M4N 3M5
来源：
Critical Care | / 15卷
关键词：
Severe Sepsis; Critical Care; Additional Data File; Acute Hospital; Critical Care Unit;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Is Drotrecogin alfa (activated) for adults with severe sepsis, cost-effective in routine clinical practice?
    Sadique, M. Zia
    Grieve, Richard
    Harrison, David A.
    Cuthbertson, Brian H.
    Rowan, Kathryn M.
    CRITICAL CARE, 2011, 15 (05)
  • [2] Clinical trials in severe sepsis with drotrecogin alfa (activated)
    Pierre-François Laterre
    Critical Care, 11
  • [3] Clinical trials in severe sepsis with drotrecogin alfa (activated)
    Laterre, Pierre-Francois
    CRITICAL CARE, 2007, 11 (Suppl 5):
  • [4] Drotrecogin alfa (activated) in severe sepsis
    Baillie, JK
    Murray, G
    NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (01): : 95 - 95
  • [5] Drotrecogin alfa (activated) in severe sepsis
    Poole, Daniele
    Rossi, Carlotta
    Addis, Antonio
    Livigni, Sergio
    Bertolini, Guido
    LANCET INFECTIOUS DISEASES, 2013, 13 (02): : 107 - 108
  • [6] Cost-effectiveness of drotrecogin alfa (activated) (Xigris™) in severe sepsis
    Angus, DC
    Linde-Zwirble, WT
    Clermont, G
    Ball, DE
    Basson, BR
    Ely, EW
    Laterre, PF
    Vincent, JL
    Bernard, GR
    van Hout, B
    CRITICAL CARE MEDICINE, 2002, 30 (02) : 493 - 493
  • [7] Cost effectiveness analysis of drotrecogin alfa (activated) as a treatment for severe sepsis
    Launois, R
    Riou-Franca, L
    Guidet, B
    Aergeter, P
    Meshaka, P
    Pinton, P
    INTENSIVE CARE MEDICINE, 2002, 28 : S161 - S161
  • [8] Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis
    Angus, DC
    Linde-Zwirble, WT
    Clermont, G
    Ball, DE
    Basson, BR
    Ely, EW
    Laterre, PF
    Vincent, JL
    Bernard, G
    van Hout, B
    CRITICAL CARE MEDICINE, 2003, 31 (01) : 1 - 11
  • [9] Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death
    Abraham, E
    Laterre, P
    Garg, R
    Levy, H
    Talwar, D
    Trzaskoma, BL
    Francois, B
    Guy, JS
    Bruckmann, M
    Rea-Neto, A
    Rossaint, R
    Perrotin, D
    Sablotzki, A
    Arkins, N
    Utterback, BG
    Macias, WL
    NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (13): : 1332 - 1341
  • [10] Introduction: severe sepsis and drotrecogin alfa (activated)
    Artigas, Antonio
    Martin, Claude D.
    CRITICAL CARE, 2007, 11 (Suppl 5)
12345